InvestorsHub Logo
Followers 594
Posts 20577
Boards Moderated 0
Alias Born 02/01/2012

Re: None

Friday, 05/12/2017 9:38:39 AM

Friday, May 12, 2017 9:38:39 AM

Post# of 8022
On May 10th, 2017, Vericel(VCEL) announced that the US FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation for ixmyelocel-T - an investigational product for the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy. The RMAT designation is a new, expedited program established under the 21st Century Cures Act to foster the development and approval of regenerative medicine products intended for the treatment of serious diseases and conditions.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VCEL News